Related Experiment Video

Updated: Mar 9, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian

Alison M Schram1, Alexia Iasonos1, David M Hyman1

  • 1Alison M. Schram, Alexia Iasonos, and David M. Hyman, Memorial Sloan Kettering Cancer Center, New York, NY.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|December 22, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K
Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

14.0K

Related Experiment Videos

Last Updated: Mar 9, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K
Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

14.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60

Articles linked to this work by shared authors, journal, and citation graph.

Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment.

Nature genetics·2026

The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Seasonal variation and risk of paclitaxel-induced hypersensitivity reactions: A retrospective cohort study.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Colorectal Cancer Risk Factors in Adults in Nigeria.

JAMA network open·2026

Outpatient rapid drug desensitisation for chemotherapy and biologic agents: high success rates in a large single-centre cohort study.

BMJ supportive & palliative care·2026

First-Line Chemoimmunotherapy and Chemotherapy Outcomes in Patients With RET Fusion-Positive Lung Cancer in LIBRETTO-431.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Effectiveness of a Multisite Oncology Financial Navigation Intervention: The Lessening the Impact of Financial Toxicity Clinical Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Expert Histopathologic Evaluation and Molecular Analyses for Ambiguous Cutaneous Melanocytic Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Vitiligo onset following anti-inflammatory biological therapy: a scoping review.

Frontiers in immunology·2026

Integrated CDK4/6 inhibitor resistance and primary-metastatic discordance in hormone receptor-positive/HER2-negative metastatic breast cancer: a translational framework focused on invasive ductal carcinoma with gastric metastasis.

Frontiers in oncology·2026

Adaptive drug resistance in melanoma is characterised by lipidome remodelling while maintaining cell membrane biophysical properties.

Cancer drug resistance (Alhambra, Calif.)·2026

Wearing-Off Effect Reports in People With Multiple Sclerosis Receiving Ocrelizumab.

International journal of MS care·2026

VCP-Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple-Negative Breast Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Saxagliptin Attenuates Thioacetamide-Induced Liver Fibrosis in Rats in Association with Changes in SIRT1/Nrf2/HO-1 Signaling, Oxidative Stress, and Apoptosis.

Toxicology mechanisms and methods·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us